Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
McKinsey
UBS
Deloitte
Covington
Argus Health
Medtronic
Fish and Richardson

Generated: January 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DARIFENACIN

« Back to Dashboard

Clinical Trials for Darifenacin

Trial ID Title Status Sponsor Phase Summary
NCT00127270 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Procter and Gamble Phase 4 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00127270 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Novartis Phase 4 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00170755 A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder Completed Novartis Phase 3 This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
NCT00170768 Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over Completed Novartis Phase 2 The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
NCT00171145 A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. Completed Novartis Phase 3 This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
NCT00171184 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder Completed Procter and Gamble Phase 4 The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Darifenacin

Condition Name

Condition Name for Darifenacin
Intervention Trials
Overactive Bladder 5
Healthy 3
Overactive Bladder Syndrome 2
Bioequivalency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Darifenacin
Intervention Trials
Urinary Bladder, Overactive 10
Multiple Sclerosis 1
Spinal Cord Injuries 1
Renal Colic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Darifenacin

Trials by Country

Trials by Country for Darifenacin
Location Trials
United States 87
Germany 8
Canada 2
Uruguay 2
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Darifenacin
Location Trials
New Jersey 6
California 5
Missouri 5
Texas 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Darifenacin

Clinical Trial Phase

Clinical Trial Phase for Darifenacin
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Darifenacin
Clinical Trial Phase Trials
Completed 13
Terminated 2
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Darifenacin

Sponsor Name

Sponsor Name for Darifenacin
Sponsor Trials
Novartis 9
Procter and Gamble 6
Center for Clinical Pharmacology Research Bdbeq S.A. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Darifenacin
Sponsor Trials
Industry 22
Other 7
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
Teva
US Army
QuintilesIMS
Deloitte
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.